{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:55:17Z","timestamp":1791363317786,"version":"4.3.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01849-9","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:43:29Z","timestamp":1791362609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and future therapies for acute myeloblastic leukemia"],"prefix":"10.1186","volume":"19","author":[{"given":"Jennifer","family":"Marvin-Peek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"10393","key":"1849_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. Elsevier B.V. 2023;401(10393):2073\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3.","journal-title":"Lancet. Elsevier B.V"},{"key":"1849_CR2","unstructured":"Surveillance Epidemiology, Program ER (SEER). SEER*Stat database: incidence - SEER research data, 8 registries, Nov 2025 Sub (1975-2023). Preprint posted online April 2026. https:\/\/seer.cancer.gov\/."},{"key":"1849_CR3","doi-asserted-by":"publisher","unstructured":"Wu B, Song F, Han X, et al. Global, regional and national epidemiology of acute myeloid leukemia (1990-2021): a statistical analysis of incidence, mortality, and DALYs. Ann Med. 2025;57(1). https:\/\/doi.org\/10.1080\/07853890.2025.2557507.","DOI":"10.1080\/07853890.2025.2557507"},{"key":"1849_CR4","doi-asserted-by":"publisher","unstructured":"El Chaer F, Bewersdorf JP, Stahl M, Zeidan AM. The global epidemiology of acute myeloid leukaemia. Nat Rev Clin Oncol. 2026;23(2). https:\/\/doi.org\/10.1038\/s41571-025-01099-7.","DOI":"10.1038\/s41571-025-01099-7"},{"key":"1849_CR5","unstructured":"Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics. Preprint posted online 2025. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-aml\/incidence#heading-Three."},{"key":"1849_CR6","doi-asserted-by":"publisher","unstructured":"Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1). https:\/\/doi.org\/10.1186\/s13045-020-00908-z.","DOI":"10.1186\/s13045-020-00908-z"},{"issue":"1","key":"1849_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75(1):46\u201367. https:\/\/doi.org\/10.3322\/caac.21873.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1849_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jtct.2026.01.019","volume":"32","author":"LC Kang","year":"2026","unstructured":"Kang LC, Fiala MA, Johnson KJ. Disparities in allogeneic hematopoietic stem cell transplantation among acute myeloid leukemia patients. Transpl Cell Ther. 2026;32(6):723\u201334. https:\/\/doi.org\/10.1016\/j.jtct.2026.01.019.","journal-title":"Transpl Cell Ther"},{"key":"1849_CR9","doi-asserted-by":"publisher","unstructured":"Morcos-Sandino M, Quezada-Ram\u00edrez SI, G\u00f3mez-De Le\u00f3n A. Advances in the treatment of acute myeloid leukemia: implications for low- and middle-income countries. Biomedicines. 2025;13(5). https:\/\/doi.org\/10.3390\/biomedicines13051221.","DOI":"10.3390\/biomedicines13051221"},{"key":"1849_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/blctt.s518005","volume":"15","author":"E Obeagu","year":"2025","unstructured":"Obeagu E. Advancing leukemia diagnosis and treatment: WHO-Supported laboratory innovations in Africa- a narrative review. Blood Lymphat Cancer. 2025;15:47\u201367. https:\/\/doi.org\/10.2147\/blctt.s518005.","journal-title":"Blood Lymphat Cancer"},{"issue":"12","key":"1849_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"issue":"23","key":"1849_CR12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/nejmoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. NEJM Evid. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/nejmoa1516192.","journal-title":"NEJM Evid"},{"key":"1849_CR13","doi-asserted-by":"publisher","unstructured":"Marvin-Peek J, Loghavi S, Issa GC, et al. The role of advanced molecular diagnostics in informing targeted therapies for AML. Hum Pathol. Published online 2026: 106179. doi: 106179. https:\/\/doi.org\/10.1016\/j.humpath.2026.106179.","DOI":"10.1016\/j.humpath.2026.106179"},{"issue":"4","key":"1849_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ajh.27236","volume":"99","author":"A Bataller","year":"2024","unstructured":"Bataller A, DiNardo CD, Bazinet A, et al. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024;99(4):792\u201396. https:\/\/doi.org\/10.1002\/ajh.27236.","journal-title":"Am J Hematol"},{"key":"1849_CR15","doi-asserted-by":"publisher","unstructured":"The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult De novo acute myeloid leukemia. NEJM Evid. 2013;368(22):2059\u201374. https:\/\/doi.org\/10.1056\/nejmoa1301689.","DOI":"10.1056\/nejmoa1301689"},{"issue":"2","key":"1849_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.annonc.2022.11.004","volume":"34","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023;34(2):141\u201351. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.004.","journal-title":"Ann Oncol"},{"key":"1849_CR17","unstructured":"Yates JW, Wallace HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC 63878) and daunorubicin (NSC 83142) therapy in acute nonlymphocytic leukemia. Cancer Chemotherrep. 1973;57(4)."},{"issue":"6","key":"1849_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood.v58.6.1203.bloodjournal5861203","volume":"58","author":"KR Rai","year":"1981","unstructured":"Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203\u201312. https:\/\/doi.org\/10.1182\/blood.v58.6.1203.bloodjournal5861203.","journal-title":"Blood"},{"key":"1849_CR19","doi-asserted-by":"crossref","unstructured":"Bickell WH, Wall MJ, Pepe PE, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med. 1994;331(17).","DOI":"10.1056\/NEJM199410063311402"},{"issue":"22","key":"1849_CR20","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349. https:\/\/doi.org\/10.1001\/jama.2009.813.","journal-title":"JAMA"},{"key":"1849_CR21","doi-asserted-by":"publisher","unstructured":"Hunault M, Pautas C, Bertoli S, et al. Intermediate-dose cytarabine as Postinduction AML therapy. NEJM Evidence. 2025;4(7). https:\/\/doi.org\/10.1056\/evidoa2400326.","DOI":"10.1056\/evidoa2400326"},{"key":"1849_CR22","doi-asserted-by":"publisher","unstructured":"Sobas MA, Turki AT, Ramiro AV, et al. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY alliance. Haematologica. 2025;110(5). https:\/\/doi.org\/10.3324\/haematol.2024.285805.","DOI":"10.3324\/haematol.2024.285805"},{"issue":"9","key":"1849_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"WS Lim","year":"2010","unstructured":"Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214\u201323. https:\/\/doi.org\/10.1016\/j.leukres.2010.01.015.","journal-title":"Leuk Res"},{"issue":"7","key":"1849_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","volume":"39","author":"HP Kim","year":"2011","unstructured":"Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39(7):741\u201350. https:\/\/doi.org\/10.1016\/j.exphem.2011.04.001.","journal-title":"Exp Hematol"},{"issue":"26","key":"1849_CR25","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, et al. Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684\u201392. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112.","journal-title":"J Clin Oncol"},{"key":"1849_CR26","doi-asserted-by":"publisher","unstructured":"Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481\u201391. https:\/\/doi.org\/10.1016\/S2352-3026(21)00134-4.","DOI":"10.1016\/S2352-3026(21)00134-4"},{"issue":"8","key":"1849_CR27","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/bloodadvances.2025019378","volume":"10","author":"S Shimony","year":"2026","unstructured":"Shimony S, Murdock HM, Keating J, et al. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. Blood Adv. 2026;10(8):2854\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2025019378.","journal-title":"Blood Adv"},{"key":"1849_CR28","doi-asserted-by":"publisher","unstructured":"Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer. 2006;107(1). https:\/\/doi.org\/10.1002\/cncr.21543.","DOI":"10.1002\/cncr.21543"},{"issue":"11","key":"1849_CR29","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1010222.","journal-title":"N Engl J Med"},{"issue":"3","key":"1849_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","volume":"32","author":"R Willemze","year":"2014","unstructured":"Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014;32(3):219\u201328. https:\/\/doi.org\/10.1200\/JCO.2013.51.8571.","journal-title":"J Clin Oncol"},{"key":"1849_CR31","unstructured":"Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988;48(2)."},{"issue":"1","key":"1849_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","volume":"11","author":"V Gandhi","year":"1993","unstructured":"Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11(1):116\u201324. https:\/\/doi.org\/10.1200\/JCO.1993.11.1.116.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1849_CR33","first-page":"653","volume":"2","author":"JF Seymour","year":"1996","unstructured":"Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996;2(4):653\u201358.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1849_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood.v87.1.256.bloodjournal871256","volume":"87","author":"V Gandhi","year":"1996","unstructured":"Gandhi V, Estey E, Keating M, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87(1):256\u201364. https:\/\/doi.org\/10.1182\/blood.v87.1.256.bloodjournal871256.","journal-title":"Blood"},{"issue":"27","key":"1849_CR35","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360\u201368. https:\/\/doi.org\/10.1200\/JCO.2012.47.4874.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1849_CR36","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH, Wilhelm-Benartzi C, Othman J, et al. Fludarabine, cytarabine, granulocyte colony-stimulating Factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol. 2024;42(10):1158\u201368. https:\/\/doi.org\/10.1200\/JCO.23.00943.","journal-title":"J Clin Oncol"},{"key":"1849_CR37","doi-asserted-by":"publisher","unstructured":"Zhang X, Han Y, Qiu H, et al. Cladribine added to Idarubicin and cytarabine as an induction regimen for patients with De novo acute myeloid leukemia: a multicenter, randomized phase III trial. Clin Cancer Res. 2025;31(8). https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2437.","DOI":"10.1158\/1078-0432.CCR-24-2437"},{"issue":"21","key":"1849_CR38","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670\u201377. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1849_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291\u201399. https:\/\/doi.org\/10.1182\/blood-2015-01-621664.","journal-title":"Blood"},{"issue":"1","key":"1849_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752.","journal-title":"Blood"},{"issue":"2","key":"1849_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet Oncol. 2018;19(2):216\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X.","journal-title":"The Lancet Oncol"},{"issue":"7","key":"1849_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in Previously untreated acute myeloid leukemia. NEJM Evid. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/nejmoa2012971.","journal-title":"NEJM Evid"},{"issue":"4","key":"1849_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"issue":"11","key":"1849_CR44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/BLOOD.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803. https:\/\/doi.org\/10.1182\/BLOOD.2019003988.","journal-title":"Blood"},{"key":"1849_CR45","doi-asserted-by":"publisher","unstructured":"Al-Kali A, Nanaa A, Viswanatha D, et al. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer J. 2023;13(1). https:\/\/doi.org\/10.1038\/s41408-023-00818-6.","DOI":"10.1038\/s41408-023-00818-6"},{"issue":"11","key":"1849_CR46","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/ajh.27070","volume":"98","author":"A Bataller","year":"2023","unstructured":"Bataller A, Loghavi S, Gerstein Y, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023;98(11):1780\u201390. https:\/\/doi.org\/10.1002\/ajh.27070.","journal-title":"Am J Hematol"},{"issue":"21","key":"1849_CR47","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2510223","volume":"394","author":"GJ Roboz","year":"2026","unstructured":"Roboz GJ, Zeidan A, Mannis GN, et al. All-oral treatment of newly diagnosed acute myeloid leukemia. NEJM Evid. 2026;394(21):2107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2510223.","journal-title":"NEJM Evid"},{"key":"1849_CR48","doi-asserted-by":"publisher","unstructured":"Bazinet A, Garcia-Manero G, Short N, et al. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. Published online 2024. doi: https:\/\/doi.org\/10.1016\/S2352-3026(24)00033-4.","DOI":"10.1016\/S2352-3026(24)00033-4"},{"issue":"20","key":"1849_CR49","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140(20):2113\u201326. https:\/\/doi.org\/10.1182\/blood.2021014304.","journal-title":"Blood"},{"issue":"4","key":"1849_CR50","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710.","journal-title":"Cancer Discov"},{"issue":"9","key":"1849_CR51","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13(9):2032\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297.","journal-title":"Cancer Discov"},{"issue":"6","key":"1849_CR52","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.stem.2026.04.012","volume":"33","author":"A Waclawiczek","year":"2026","unstructured":"Waclawiczek A, Lepp\u00e4 AM, Renders S, et al. Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell STEM Cell. 2026;33(6):982\u201399.e8. https:\/\/doi.org\/10.1016\/j.stem.2026.04.012.","journal-title":"Cell STEM Cell"},{"issue":"21","key":"1849_CR53","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373. https:\/\/doi.org\/10.1182\/blood.2024025409.","journal-title":"Blood"},{"key":"1849_CR54","doi-asserted-by":"publisher","unstructured":"Lachowiez CA, Zeidner JF, Othman J, et al. Risk prognostication after hypomethylating agents combined with venetoclax in AML: the PRISM risk Model. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-26-00347. July 2026.","DOI":"10.1200\/JCO-26-00347"},{"key":"1849_CR55","doi-asserted-by":"publisher","unstructured":"Kadia TM, Cortes J, Ravandi F, et al. Phase II single-arm trial of cladribine and low-dose cytarabine alternating with decitabine as frontline therapy for older patients with acute myeloid leukemia. Lancet Haematol. 2018;5(9):e411\u201321. https:\/\/doi.org\/10.1016\/S2352-3026(18)30132-7.","DOI":"10.1016\/S2352-3026(18)30132-7"},{"issue":"7","key":"1849_CR56","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/ajh.70328","volume":"101","author":"TM Kadia","year":"2026","unstructured":"Kadia TM, Bataller A, Bazinet A, et al. Cladribine with low-dose cytarabine and venetoclax alternating with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia. Am J Hematol. 2026, n\/a(n\/a). doi: 101(7):1737\u201347. https:\/\/doi.org\/10.1002\/ajh.70328.","journal-title":"Am J Hematol"},{"issue":"28","key":"1849_CR57","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1200\/JCO.2007.14.0418","volume":"26","author":"A Neubauer","year":"2008","unstructured":"Neubauer A, Maharry K, Mr\u00f3zek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a cancer and leukemia group B study. J Clin Oncol. 2008;26(28):4603\u201309. https:\/\/doi.org\/10.1200\/JCO.2007.14.0418.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1849_CR58","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, L\u00f6wenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442\u201352. https:\/\/doi.org\/10.1002\/cncr.21326.","journal-title":"Cancer"},{"issue":"24","key":"1849_CR59","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854\u201360. https:\/\/doi.org\/10.1182\/blood-2013-01-466706.","journal-title":"Blood"},{"issue":"9825","key":"1849_CR60","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(12)60485-1.","journal-title":"Lancet"},{"issue":"4","key":"1849_CR61","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369\u201377. https:\/\/doi.org\/10.1200\/JCO.2010.31.4310.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1849_CR62","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3324\/haematol.2016.141937","volume":"101","author":"A Burnett","year":"2016","unstructured":"Burnett A, Cavenagh J, Russell N, et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 trial. Haematologica. 2016;101(6):724\u201331. https:\/\/doi.org\/10.3324\/haematol.2016.141937.","journal-title":"Haematologica"},{"issue":"9","key":"1849_CR63","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncol. 2014;15(9):986\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(14)70281-5.","journal-title":"The Lancet Oncol"},{"issue":"10","key":"1849_CR64","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ajh.23795","volume":"89","author":"G Borthakur","year":"2014","unstructured":"Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O\u2019Brien S, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89(10):964\u201368. https:\/\/doi.org\/10.1002\/ajh.23795.","journal-title":"Am J Hematol"},{"issue":"4","key":"1849_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1158\/2643-3230.BCD-25-0477","volume":"7","author":"J Senapati","year":"2026","unstructured":"Senapati J, Kantarjian HM, Ayoub E, et al. Integrated analysis of Genomics, molecular responses, and outcomes of CBF-AML with FLAG-Based therapy on a phase II trial. Blood Cancer Discov. 2026;7(4):572\u201385. https:\/\/doi.org\/10.1158\/2643-3230.BCD-25-0477.","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"1849_CR66","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","volume":"63","author":"NJ Short","year":"2022","unstructured":"Short NJ, Borthakur G, Pemmaraju N, et al. A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia. Leuk Lymphoma. 2022;63(9):2161\u201370. https:\/\/doi.org\/10.1080\/10428194.2022.2062345.","journal-title":"Leuk Lymphoma"},{"key":"1849_CR67","doi-asserted-by":"publisher","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, K\u00fchn MWM, Schroeder T, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10(7):e495\u2013509. https:\/\/doi.org\/10.1016\/S2352-3026(23)00089-3.","DOI":"10.1016\/S2352-3026(23)00089-3"},{"issue":"24","key":"1849_CR68","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1182\/bloodadvances.2025017244","volume":"9","author":"N Russell","year":"2025","unstructured":"Russell N, Othman J, Cumming O, et al. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML. Blood Adv. 2025;9(24):6455\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2025017244.","journal-title":"Blood Adv"},{"key":"1849_CR69","doi-asserted-by":"publisher","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2). https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","DOI":"10.1038\/s41375-018-0357-9"},{"issue":"9","key":"1849_CR70","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Venditti A, Voso MT, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972\u201379. https:\/\/doi.org\/10.1200\/JCO.2015.64.0060.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1849_CR71","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/nejmoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. NEJM Evid. 2017;377(5):454\u201364. https:\/\/doi.org\/10.1056\/nejmoa1614359.","journal-title":"NEJM Evid"},{"key":"1849_CR72","doi-asserted-by":"publisher","unstructured":"Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML. New England Journal of Medicine. 2022;386(19). https:\/\/doi.org\/10.1056\/nejmx220003.","DOI":"10.1056\/nejmx220003"},{"issue":"10388","key":"1849_CR73","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6.","journal-title":"Lancet"},{"issue":"25","key":"1849_CR74","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/nejmoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1 -mutated relapsed or refractory AML. NEJM Evid. 2018;378(25):2386\u201398. https:\/\/doi.org\/10.1056\/nejmoa1716984.","journal-title":"NEJM Evid"},{"issue":"7","key":"1849_CR75","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463\u201371. https:\/\/doi.org\/10.1182\/blood.2019002140.","journal-title":"Blood"},{"issue":"16","key":"1849_CR76","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/nejmoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1 -mutated acute myeloid leukemia. NEJM Evid. 2022;386(16):1519\u201331. https:\/\/doi.org\/10.1056\/nejmoa2117344.","journal-title":"NEJM Evid"},{"issue":"16_suppl","key":"1849_CR77","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1200\/jco.2023.41.16_suppl.7012","volume":"41","author":"S De Botton","year":"2023","unstructured":"De Botton S, Montesinos P, Vives Polo S, et al. Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. J Clin Oncol. 2023;41(16_suppl):7012\u20137012. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.7012.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1849_CR78","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/BLOODADVANCES.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton S, Fenaux P, Yee K, R\u00e9cher C, Wei AH, Montesinos P, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117\u201327. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2022009411.","journal-title":"Blood Adv"},{"issue":"6","key":"1849_CR79","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331. https:\/\/doi.org\/10.1182\/blood-2017-04-779405.","journal-title":"Blood"},{"issue":"1","key":"1849_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A -Rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1849_CR81","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1182\/blood.2025028357","volume":"146","author":"ML Arellano","year":"2025","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025;146(9):1065\u201377. https:\/\/doi.org\/10.1182\/blood.2025028357.","journal-title":"Blood"},{"issue":"10","key":"1849_CR82","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. The Lancet Oncol. 2024;25(10):1310\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(24)00386-3.","journal-title":"The Lancet Oncol"},{"issue":"9","key":"1849_CR83","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","volume":"35","author":"RA Larson","year":"2021","unstructured":"Larson RA, Mandrekar SJ, Huebner LJ, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the alliance CALGB 10603\/RATIFY trial. Leukemia. 2021;35(9):2539\u201351. https:\/\/doi.org\/10.1038\/s41375-021-01179-4.","journal-title":"Leukemia"},{"issue":"12","key":"1849_CR84","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/BLOODADVANCES.2025017738","volume":"10","author":"MJ Levis","year":"2026","unstructured":"Levis MJ, Erba HP, Montesinos P, et al. Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. Blood Adv. 2026;10(12):4144\u201359. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2025017738.","journal-title":"Blood Adv"},{"key":"1849_CR85","unstructured":"Raaijmakers M, Ossenkoppele G, Gradowska P, et al. Gilteritinib versus midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia eligible for intensive therapy: results from the phase 3 HOVON156\/AMLSG28-18\/PASHA trial. Hemasphere. 2026;10(S1):LB5005. https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4214972\/marc.raaijmakers.gilteritinib.versus.midostaurin.in.patients.with.newly.html."},{"issue":"17","key":"1849_CR86","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586.","journal-title":"Blood"},{"key":"1849_CR87","doi-asserted-by":"publisher","unstructured":"Wang ES, Montesinos P, Minden MD, et al. Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2026.301112. September 2026.","DOI":"10.3324\/haematol.2026.301112"},{"key":"1849_CR88","doi-asserted-by":"publisher","unstructured":"Short NJ, Daver N, Dinardo CD, et al. Azacitidine, venetoclax, and Gilteritinib in newly diagnosed and relapsed or refractory FLT3 -mutated AML. J Clin Oncol. Published online 2024. doi: https:\/\/doi.org\/10.1200\/jco.23.01911.","DOI":"10.1200\/jco.23.01911"},{"key":"1849_CR89","doi-asserted-by":"publisher","unstructured":"Short NJ, Kantarjian HM, Daver NG, et al. Long-Term outcomes of Azacitidine, venetoclax and gilteritinib in newly diagnosed FLT3-mutated AML. Blood Adv. Published online May 27, 2026: bloodadvances.2026019841. doi: https:\/\/doi.org\/10.1182\/bloodadvances.2026019841.","DOI":"10.1182\/bloodadvances.2026019841"},{"issue":"16_suppl","key":"1849_CR90","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1200\/JCO.2026.44.16_suppl.6504","volume":"44","author":"M Yilmaz","year":"2026","unstructured":"Yilmaz M, Muftuoglu M, DiNardo CD, et al. Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed\/refractory FLT3-mutated AML. J Clin Oncol. 2026;44(16_suppl):6504. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.6504.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1849_CR91","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood.2025032829","volume":"148","author":"N Duployez","year":"2026","unstructured":"Duployez N, Joudinaud R, Boudry A, et al. Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy. Blood. 2026;148(5):598\u2013609. https:\/\/doi.org\/10.1182\/blood.2025032829.","journal-title":"Blood"},{"issue":"1","key":"1849_CR92","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO-25-01841","volume":"44","author":"P Montesinos","year":"2025","unstructured":"Montesinos P, Rodr\u00edguez-Veiga R, Bergua JM, et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative AML: the randomized, double-blind, placebo-controlled, phase II QUIWI study. J Clin Oncol. 2025;44(1):42\u201353. https:\/\/doi.org\/10.1200\/JCO-25-01841.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1849_CR93","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2024-203459","volume":"144","author":"IM Bouligny","year":"2024","unstructured":"Bouligny IM, Kantarjian HM, Yilmaz M, et al. A phase II trial of venetoclax in combination with cladribine, Idarubicin, and cytarabine in newly diagnosed acute myeloid leukemia and High-risk myelodysplastic syndrome. Blood. 2024;144(Supplement 1):734. https:\/\/doi.org\/10.1182\/blood-2024-203459.","journal-title":"Blood"},{"key":"1849_CR94","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Jen WY, Takahashi K, et al. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia. Published online 2025. doi: 39(4):854\u201363. https:\/\/doi.org\/10.1038\/s41375-025-02531-8.","DOI":"10.1038\/s41375-025-02531-8"},{"key":"1849_CR95","doi-asserted-by":"publisher","unstructured":"Montesinos P, Cheong JW, Daver NG, et al. QuANTUM-Wild: a phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD-negative acute myeloid leukemia (AML). J Clin Oncol. 2025;43(16_suppl):TPS6580\u20136580. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS6580.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6580"},{"issue":"Supplement 1","key":"1849_CR96","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2025-6","volume":"146","author":"A Fathi","year":"2025","unstructured":"Fathi A, Perl A, Fell G, et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146(Supplement 1):6. https:\/\/doi.org\/10.1182\/blood-2025-6.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR97","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2025-992","volume":"146","author":"E Stein","year":"2025","unstructured":"Stein E, DiNardo C, Fathi A, et al. Updated response and safety analyses from a phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) acute myeloid leukemia with isocitrate dehydrogenase (IDH)1 mutation. Blood. 2025;146(Supplement 1):992. https:\/\/doi.org\/10.1182\/blood-2025-992.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR98","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1182\/blood-2024-207476","volume":"146","author":"J Croden","year":"2024","unstructured":"Croden J, Hammond D, Chien KS, et al. Interim results of the phase II study investigating CPX-351 in combination with ivosidenib for patients with IDH1-mutated acute myeloid leukemia and High-risk myelodysplastic syndrome. Blood. 2024;146(Supplement 1):4271\u20134271. https:\/\/doi.org\/10.1182\/blood-2024-207476.","journal-title":"Blood"},{"issue":"11","key":"1849_CR99","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. The Lancet Oncol. 2021;22(11):1597\u2013608. https:\/\/doi.org\/10.1016\/S1470-2045(21)00494-0.","journal-title":"The Lancet Oncol"},{"issue":"16_suppl","key":"1849_CR100","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1200\/JCO.2026.44.16_suppl.6503","volume":"44","author":"J Marvin-Peek","year":"2026","unstructured":"Marvin-Peek J, Garcia JS, Borthakur G, et al. A multicenter phase Ib\/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML). J Clin Oncol. 2026;44(16_suppl):6503. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.6503.","journal-title":"J Clin Oncol"},{"key":"1849_CR101","doi-asserted-by":"publisher","unstructured":"Marvin-Peek J, Maiti A, Alvarado Y, et al. A phase Ib\/2 trial of an all-oral \u201ctriplet\u201d regimen for IDH-mutated myeloid malignancies: decitabine\/cedazuridine and venetoclax in combination with ivosidenib\/enasidenib. Hemasphere. Published online 2025: e 2622.25:S182. https:\/\/doi.org\/10.1016\/S2152-2650(25)00495-1.","DOI":"10.1016\/S2152-2650(25)00495-1"},{"issue":"1","key":"1849_CR102","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-024-01657-z","volume":"18","author":"JE Cortes","year":"2025","unstructured":"Cortes JE, Roboz GJ, Baer MR, et al. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1\/2 trial. J Hematol Oncol. 2025;18(1):7. https:\/\/doi.org\/10.1186\/s13045-024-01657-z.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"1849_CR103","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2025-763","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Zeidner J, Watts J, et al. Monotherapy update from phase 1 portion in Phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2025;146(Supplement 1):763. https:\/\/doi.org\/10.1182\/blood-2025-763.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR104","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/blood-2024-207106","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle E, Recher C, Abdul-Hay M, et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in Relapsed\/Refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood. 2024;144(Supplement 1):212\u2013212. https:\/\/doi.org\/10.1182\/blood-2024-207106.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR105","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-198959","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu D, Wang Y, Chen S, et al. A first-in-human phase 1\/2 study of the menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Blood. 2024;144(Supplement 1):2879\u20132879. https:\/\/doi.org\/10.1182\/blood-2024-198959.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR106","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1182\/blood-2025-5206","volume":"146","author":"A Mims","year":"2025","unstructured":"Mims A, Wei L, McLaughlin E, et al. Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia: preliminary results from the phase 1b etctn 10596 study. Blood. 2025;146(Supplement 1):5206. https:\/\/doi.org\/10.1182\/blood-2025-5206.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR107","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1182\/blood-2025-3425","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Shultz C, Hunter B, et al. Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708. Blood. 2025;146(Supplement 1):3425. https:\/\/doi.org\/10.1182\/blood-2025-3425.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR108","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2024-198218","volume":"144","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Wang ES, Issa GC, et al. Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144(Supplement 1):214. https:\/\/doi.org\/10.1182\/blood-2024-198218.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR109","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1182\/blood-2025-5199","volume":"146","author":"H D\u00f6hner","year":"2025","unstructured":"D\u00f6hner H, Schuh A, Recher C, et al. Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146(Supplement 1):5199. https:\/\/doi.org\/10.1182\/blood-2025-5199.","journal-title":"Blood"},{"key":"1849_CR110","unstructured":"Wei AH, Reyner JE, Garciaz S, et al. RP2D determination of Bleximenib in combination with VEN+AZA: phase 1B study in ND & R\/R AML with KMT2A\/NPM1 alterations. in: EHA2025 Congress. 2025. https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159214\/."},{"issue":"23","key":"1849_CR111","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO-25-00914","volume":"43","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Lin TL, Welkie RL, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025;43(23):2606\u201315. https:\/\/doi.org\/10.1200\/JCO-25-00914.","journal-title":"J Clin Oncol"},{"key":"1849_CR112","doi-asserted-by":"publisher","unstructured":"Huls GA, K\u00fchn MWM, Vyas P, et al. A phase 3 study of revumenib plus venetoclax\/azacitidine in adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2\/HO177\/AMLSG35-24\/ACT-HOV-AML-002). J Clin Oncol. 2026;44(16_suppl):TPS6600\u20136600. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.TPS6600.","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS6600"},{"issue":"22","key":"1849_CR113","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1200\/JCO-26-01159","volume":"44","author":"GC Issa","year":"2026","unstructured":"Issa GC, Cuglievan B, El Hajjar G, Jen WY, Bataller A, Short NJ, et al. All-oral combination of Revumenib, decitabine, and venetoclax for relapsed or refractory AML (SAVE). J Clin Oncol. 2026;44(22):2110\u201320. https:\/\/doi.org\/10.1200\/JCO-26-01159.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1849_CR114","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2025-47","volume":"146","author":"WY Jen","year":"2025","unstructured":"Jen WY, DiNardo C, Short N, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146(Supplement 1):47. https:\/\/doi.org\/10.1182\/blood-2025-47.","journal-title":"Blood"},{"key":"1849_CR115","doi-asserted-by":"publisher","unstructured":"Wang ES, Erba HP, Zeidan AM, et al. Ziftomenib with venetoclax and azacitidine in relapsed\/refractory NPM1-mutated acute myeloid leukemia. Blood. 147(17):2019\u20132019. https:\/\/doi.org\/10.1182\/blood.2026034043. blood.2026034043. June 2, 2026.","DOI":"10.1182\/blood.2026034043"},{"issue":"Supplement 1","key":"1849_CR116","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2025-766","volume":"146","author":"G Roboz","year":"2025","unstructured":"Roboz G, Wang E, Fathi A, et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007. Blood. 2025;146(Supplement 1):766. https:\/\/doi.org\/10.1182\/blood-2025-766.","journal-title":"Blood"},{"issue":"3","key":"1849_CR117","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","volume":"8","author":"AA Lane","year":"2024","unstructured":"Lane AA, Garcia JS, Raulston EG, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024;8(3):591\u2013602. https:\/\/doi.org\/10.1182\/bloodadvances.2023011721.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1849_CR118","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2025-651","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Advani A, De La Fuente Burguera A, et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia. Blood. 2025;146(Supplement 1):651. https:\/\/doi.org\/10.1182\/blood-2025-651.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR119","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1182\/blood-2025-5198","volume":"146","author":"J Watts","year":"2025","unstructured":"Watts J, Borthakur G, Lin T, et al. A dose optimization phase 1b\/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIR\u00d2 molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy. Blood. 2025;146(Supplement 1):5198. https:\/\/doi.org\/10.1182\/blood-2025-5198.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR120","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2025-652","volume":"146","author":"S Garciaz","year":"2025","unstructured":"Garciaz S, Dumas PY, Peterlin P, et al. \u03b39\u03b42 T-cell (\u03b39\u03b42TC) activation with ICT01 and azacitidine-venetoclax (aza-ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): results from the phase 1\/2 study eviction. Blood. 2025;146(Supplement 1):652. https:\/\/doi.org\/10.1182\/blood-2025-652.","journal-title":"Blood"},{"issue":"1","key":"1849_CR121","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1309\/AJCPD7NR2RMNQDVF","volume":"135","author":"KP Patel","year":"2011","unstructured":"Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135(1):35\u201345. https:\/\/doi.org\/10.1309\/AJCPD7NR2RMNQDVF.","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"1849_CR122","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/nejmoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. NEJM Evid. 2009;361(11):1058\u201366. https:\/\/doi.org\/10.1056\/nejmoa0903840.","journal-title":"NEJM Evid"},{"issue":"8","key":"1849_CR123","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD Dinardo","year":"2015","unstructured":"Dinardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732\u201336. https:\/\/doi.org\/10.1002\/ajh.24072.","journal-title":"Am J Hematol"},{"issue":"7274","key":"1849_CR124","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344. https:\/\/doi.org\/10.1038\/nature08617.","journal-title":"Nature"},{"issue":"6","key":"1849_CR125","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a Hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553\u201367. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015.","journal-title":"Cancer Cell"},{"issue":"3","key":"1849_CR126","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225\u201334. https:\/\/doi.org\/10.1016\/j.ccr.2010.01.020.","journal-title":"Cancer Cell"},{"key":"1849_CR127","doi-asserted-by":"publisher","unstructured":"Dinardo CD, Marvin-Peek J, Loghavi S, et al. Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML. J Clin Oncol. Published online 2025. doi: 43(24):2692\u201399. https:\/\/doi.org\/10.1200\/JCO-25-00640.","DOI":"10.1200\/JCO-25-00640"},{"issue":"13","key":"1849_CR128","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137(13):1792\u2013803. https:\/\/doi.org\/10.1182\/blood.2020007233.","journal-title":"Blood"},{"issue":"3","key":"1849_CR129","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8(3):277\u201384. https:\/\/doi.org\/10.1038\/nchembio.773.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"1849_CR130","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"V Krivtsov A","year":"2019","unstructured":"Krivtsov A V, Evans K, Gadrey JY, et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-Rearranged leukemia. Cancer Cell. 2019;36(6):660\u201373.e11. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.001.","journal-title":"Cancer Cell"},{"key":"1849_CR131","doi-asserted-by":"publisher","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9). https:\/\/doi.org\/10.1038\/s41375-021-01309-y.","DOI":"10.1038\/s41375-021-01309-y"},{"key":"1849_CR132","doi-asserted-by":"publisher","unstructured":"Sparbier CE, Gillespie A, Gomez J, et al. Targeting Menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes. Nat Cell Biol. 2023;25(2). https:\/\/doi.org\/10.1038\/s41556-022-01056-x.","DOI":"10.1038\/s41556-022-01056-x"},{"key":"1849_CR133","doi-asserted-by":"publisher","unstructured":"Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(9). https:\/\/doi.org\/10.1038\/s41408-021-00557-6.","DOI":"10.1038\/s41408-021-00557-6"},{"issue":"7954","key":"1849_CR134","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u201324. https:\/\/doi.org\/10.1038\/s41586-023-05812-3.","journal-title":"Nature"},{"issue":"31","key":"1849_CR135","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO-25-01694","volume":"43","author":"ES Wang","year":"2025","unstructured":"Wang ES, Montesinos P, Foran J, et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol. 2025;43(31):3381\u201390. https:\/\/doi.org\/10.1200\/JCO-25-01694.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1849_CR136","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, et al. Phase 1 results: first-in-human phase 1\/2 study of the Menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024;144(Supplement 1):213\u2013213. https:\/\/doi.org\/10.1182\/blood-2024-194827.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1849_CR137","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-198959","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu D, Wang Y, Chen S, et al. A first-in-human phase 1\/2 study of the menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Blood. 2024;144(Supplement 1):2879. https:\/\/doi.org\/10.1182\/blood-2024-198959.","journal-title":"Blood"},{"issue":"2","key":"1849_CR138","doi-asserted-by":"publisher","first-page":"100201","DOI":"10.1016\/j.bneo.2026.100201","volume":"3","author":"LE Aguirre","year":"2026","unstructured":"Aguirre LE, Bewersdorf JP, Liu Y, et al. Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood Neoplasia. 2026;3(2):100201. https:\/\/doi.org\/10.1016\/j.bneo.2026.100201.","journal-title":"Blood Neoplasia"},{"key":"1849_CR139","doi-asserted-by":"publisher","unstructured":"Daver NG, Iqbal S, Renard C, et al. Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol. 2023;16(1). https:\/\/doi.org\/10.1186\/s13045-023-01417-5.","DOI":"10.1186\/s13045-023-01417-5"},{"issue":"30","key":"1849_CR140","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC, Roberts AW, Reynolds J, et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;38(30):3506\u201317. https:\/\/doi.org\/10.1200\/JCO.20.00572.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1849_CR141","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/bloodadvances.2024014900","volume":"9","author":"CC Chua","year":"2025","unstructured":"Chua CC, Loo S, Fong CY, et al. Final analysis of the phase 1b chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT). Blood Adv. 2025;9(8):1827\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2024014900.","journal-title":"Blood Adv"},{"key":"1849_CR142","doi-asserted-by":"publisher","unstructured":"Wang H, Mao L, Yang M, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9(6):e415\u201324. https:\/\/doi.org\/10.1016\/S2352-3026(22)00106-5.","DOI":"10.1016\/S2352-3026(22)00106-5"},{"issue":"8","key":"1849_CR143","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/ajh.26601","volume":"97","author":"CD DiNardo","year":"2022","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97(8):1035\u201343. https:\/\/doi.org\/10.1002\/ajh.26601.","journal-title":"Am J Hematol"},{"key":"1849_CR144","doi-asserted-by":"publisher","unstructured":"Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(8):e552\u201361. https:\/\/doi.org\/10.1016\/S2352-3026(21)00192-7.","DOI":"10.1016\/S2352-3026(21)00192-7"},{"issue":"2","key":"1849_CR145","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/bjh.70253","volume":"208","author":"BJ Lee","year":"2026","unstructured":"Lee BJ, Griffin SP, Doh J, et al. Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia. Br J Haematol. 2026;208(2):570\u201378. https:\/\/doi.org\/10.1111\/bjh.70253.","journal-title":"Br J Haematol"},{"key":"1849_CR146","doi-asserted-by":"publisher","unstructured":"Lachowiez CA, Reville PK, Kantarjian H, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9(5):e350\u201360. https:\/\/doi.org\/10.1016\/S2352-3026(22)00076-X.","DOI":"10.1016\/S2352-3026(22)00076-X"},{"issue":"4","key":"1849_CR147","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ajh.70250","volume":"101","author":"J Marvin-Peek","year":"2026","unstructured":"Marvin-Peek J, Kantarjian H, Jen WY, et al. Evaluating the impact of fewer frontline intensive chemotherapy plus venetoclax consolidation cycles on outcomes in AML. Am J Hematol. 2026;101(4):917\u201322. https:\/\/doi.org\/10.1002\/ajh.70250.","journal-title":"Am J Hematol"},{"issue":"19","key":"1849_CR148","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","volume":"1","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian H, Borthakur G, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1(19):1546\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2017009019.","journal-title":"Blood Adv"},{"issue":"25","key":"1849_CR149","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/blood.2020006575","volume":"136","author":"H Miao","year":"2020","unstructured":"Miao H, Kim EG, Chen D, et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood. 2020;136(25):2958\u201363. https:\/\/doi.org\/10.1182\/blood.2020006575.","journal-title":"Blood"},{"issue":"21","key":"1849_CR150","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/BLOOD.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama MM, Steiner M, Rausch J, Sasca D, Sch\u00f6nfeld J, Kunz K, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136(21):2442\u201356. https:\/\/doi.org\/10.1182\/BLOOD.2020005037.","journal-title":"Blood"},{"issue":"9","key":"1849_CR151","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe S, Wang H, DiNardo CD, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894\u2013905. https:\/\/doi.org\/10.1182\/bloodadvances.2020001503.","journal-title":"Blood Adv"},{"issue":"3","key":"1849_CR152","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/cncr.33293","volume":"127","author":"M Shoukier","year":"2021","unstructured":"Shoukier M, Kadia T, Konopleva M, et al. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021;127(3):381\u201390. https:\/\/doi.org\/10.1002\/cncr.33293.","journal-title":"Cancer"},{"issue":"9","key":"1849_CR153","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2602804","volume":"395","author":"F Amir","year":"2026","unstructured":"Amir F, Alexander P, Geoffrey F, et al. Azacitidine-venetoclax or induction chemotherapy for acute myeloid leukemia. N Engl J Med. 2026;395(9):845\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2602804.","journal-title":"NEJM Evid"},{"issue":"Supplement 1","key":"1849_CR154","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1182\/blood-2024-202643","volume":"144","author":"H Goulart","year":"2024","unstructured":"Goulart H, Bazinet A, Rausch CR, et al. Clinical outcomes of patients with AML receiving lower intensity chemotherapy with or without the Use of granulocyte-colony stimulating Factor (GCSF). Blood. 2024;144(Supplement 1):5968. https:\/\/doi.org\/10.1182\/blood-2024-202643.","journal-title":"Blood"},{"issue":"13","key":"1849_CR155","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","volume":"6","author":"CC Chua","year":"2022","unstructured":"Chua CC, Hammond D, Kent A, et al. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022;6(13):3879\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2022007083.","journal-title":"Blood Adv"},{"issue":"22","key":"1849_CR156","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D, Jovanovic J V, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650\u201358. https:\/\/doi.org\/10.1200\/JCO.2008.20.1533.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1849_CR157","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood.2025030816","volume":"147","author":"AS Platzbecker","year":"2026","unstructured":"Platzbecker AS, Georgi JA, Middeke JM, et al. Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial. Blood. 2026;147(10):1098\u2013110. https:\/\/doi.org\/10.1182\/blood.2025030816.","journal-title":"Blood"},{"key":"1849_CR158","doi-asserted-by":"publisher","unstructured":"Wei AH, Iland HJ, DiNardo CD, Reynolds J. Measurable residual disease intervention in AML: a new therapeutic horizon. Blood. 2026;147(1). https:\/\/doi.org\/10.1182\/blood.2025029010.","DOI":"10.1182\/blood.2025029010"},{"key":"1849_CR159","doi-asserted-by":"publisher","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1). https:\/\/doi.org\/10.1182\/blood-2015-07-604546.","DOI":"10.1182\/blood-2015-07-604546"},{"issue":"19","key":"1849_CR160","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143(19):1931\u201336. https:\/\/doi.org\/10.1182\/blood.2023023096.","journal-title":"Blood"},{"issue":"7","key":"1849_CR161","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1073\/pnas.1812963116","volume":"116","author":"RC Hillig","year":"2019","unstructured":"Hillig RC, Sautier B, Schroeder J, et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A. 2019;116(7):2551\u201360. https:\/\/doi.org\/10.1073\/pnas.1812963116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1849_CR162","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clml.2018.12.009","volume":"19","author":"A Maiti","year":"2019","unstructured":"Maiti A, Naqvi K, Kadia TM, et al. Phase II trial of MEK inhibitor binimetinib (MEK162) in RAS-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. Clin Lymphoma Myeloma Leuk. 2019;19(3):142\u20138.e1. https:\/\/doi.org\/10.1016\/j.clml.2018.12.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1849_CR163","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000525566","volume":"145","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Ravandi F, Pemmaraju N, et al. A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations. Acta Haematol. 2022;145(5):529\u201336. https:\/\/doi.org\/10.1159\/000525566.","journal-title":"Acta Haematol"},{"issue":"6","key":"1849_CR164","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","volume":"68","author":"J Cregg","year":"2025","unstructured":"Cregg J, Edwards A V, Chang S, et al. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, Noncovalent Tri-complex inhibitor for the treatment of patients with multiple RAS-Addicted cancers. J Med Chem. 2025;68(6):6064\u201383. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02314.","journal-title":"J Med Chem"},{"issue":"3","key":"1849_CR165","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood.2025030558","volume":"147","author":"B Popescu","year":"2026","unstructured":"Popescu B, Jones MF, Piao M, et al. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026;147(3):276\u201389. https:\/\/doi.org\/10.1182\/blood.2025030558.","journal-title":"Blood"},{"issue":"4","key":"1849_CR166","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2605555","volume":"395","author":"M Oe","year":"2026","unstructured":"Oe M, Wz A, Ha E, et al. Daraxonrasib or chemotherapy in Previously treated metastatic pancreatic cancer. NEJM Evid. 2026;395(4):325\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2605555.","journal-title":"NEJM Evid"},{"key":"1849_CR167","doi-asserted-by":"publisher","unstructured":"Luna-Ram\u00edrez L, Garc\u00eda-Navas R, Santos E, Baltan\u00e1s FC. SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers. Mol Cancer. Published online 2026. doi: 25(1). https:\/\/doi.org\/10.1186\/s12943-026-02632-7.","DOI":"10.1186\/s12943-026-02632-7"},{"issue":"6_Supplement","key":"1849_CR168","doi-asserted-by":"publisher","first-page":"6564","DOI":"10.1158\/1538-7445.AM2024-6564","volume":"84","author":"K Kostyrko","year":"2024","unstructured":"Kostyrko K, Hinkel M, Rees MG, et al. Abstract, 6564: SOS1 inhibitor treatment improves response to venetoclax in acute myeloid leukemia. Cancer Res. 2024;84(6_Supplement):6564. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-6564.","journal-title":"Cancer Res"},{"issue":"15","key":"1849_CR169","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347\u201354. https:\/\/doi.org\/10.1182\/blood.2021014472.","journal-title":"Blood"},{"issue":"22","key":"1849_CR170","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681\u201389. https:\/\/doi.org\/10.1182\/bloodadvances.2020003120.","journal-title":"Blood Adv"},{"issue":"19","key":"1849_CR171","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/cncr.33675","volume":"127","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, Shoukier M, Konopleva M, et al. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021;127(19):3541\u201351. https:\/\/doi.org\/10.1002\/cncr.33675.","journal-title":"Cancer"},{"issue":"26","key":"1849_CR172","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","volume":"131","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Chilkulwar A, Saliba RM, et al. Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations. Blood. 2018;131(26):2989\u201392. https:\/\/doi.org\/10.1182\/blood-2018-02-832360.","journal-title":"Blood"},{"key":"1849_CR173","unstructured":"Aprea Therapeutics. Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant Myelodysplastic syndromes (MDS). Press Release. 2020, December."},{"issue":"5","key":"1849_CR174","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146(5):601\u201311. https:\/\/doi.org\/10.1182\/blood.2024027506.","journal-title":"Blood"},{"issue":"10","key":"1849_CR175","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1080\/10428194.2024.2363440","volume":"65","author":"G Gener-Ricos","year":"2024","unstructured":"Gener-Ricos G, Bewersdorf JP, Loghavi S, et al. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma. 2024;65(10):1511\u201315. https:\/\/doi.org\/10.1080\/10428194.2024.2363440.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"1849_CR176","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.2025028935","volume":"146","author":"BZ Carter","year":"2025","unstructured":"Carter BZ, Mak PY, Ayoub E, et al. Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. Blood. 2025;146(21):2574\u201388. https:\/\/doi.org\/10.1182\/blood.2025028935.","journal-title":"Blood"},{"issue":"11","key":"1849_CR177","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1021\/acsptsci.2c00164","volume":"5","author":"JR Stephenson Clarke","year":"2022","unstructured":"Stephenson Clarke JR, Douglas LR, Duriez PJ, et al. Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C. ACS Pharmacol Transl Sci. 2022;5(11):1169\u201380. https:\/\/doi.org\/10.1021\/acsptsci.2c00164.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"9","key":"1849_CR178","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1056\/NEJMoa2508820","volume":"394","author":"E De","year":"2026","unstructured":"De E, Sg I, Pa R, et al. Phase 1 study of rezatapopt, a p53 reactivator, in TP53 Y220C-Mutated tumors. NEJM Evid. 2026;394(9):872\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2508820.","journal-title":"NEJM Evid"},{"issue":"16_suppl","key":"1849_CR179","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/JCO.2026.44.16_suppl.2506","volume":"44","author":"R Surana","year":"2026","unstructured":"Surana R, Schoenfeld AJ, Kamgar M, et al. Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H-mutated unresectable advanced solid tumors. J Clin Oncol. 2026;44(16_suppl):2506. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.2506.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1849_CR180","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1158\/1078-0432.ccr-25-0229","volume":"31","author":"N Daver","year":"2025","unstructured":"Daver N, Senapati J, Kantarjian HM, et al. Azacitidine, venetoclax, and magrolimab in newly diagnosed and relapsed refractory acute myeloid leukemia: phase Ib\/II study and correlative analysis. Clin Cancer Res. 2025;31(12):2386\u201398. https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-0229.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1849_CR181","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/blood.2024027117","volume":"146","author":"Z Wang","year":"2025","unstructured":"Wang Z, Skwarska A, Poigaialwar G, et al. Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML. Blood. 2025;146(3):341\u201355. https:\/\/doi.org\/10.1182\/blood.2024027117.","journal-title":"Blood"},{"issue":"7","key":"1849_CR182","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9(7):910\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0125.","journal-title":"Cancer Discov"},{"issue":"3","key":"1849_CR183","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","volume":"30","author":"NJ Lakhani","year":"2024","unstructured":"Lakhani NJ, Rasco D, Wang H, et al. First-in-human study with preclinical data of BCL-2\/ BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors. Clin Cancer Res. 2024;30(3):506\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1525.","journal-title":"Clin Cancer Res"},{"key":"1849_CR184","unstructured":"Mu\u00f1oz L, Nomded\u00e9u JF, L\u00f3pez O, et al. Interleukin-3 receptor \u03b1 chain (CD123) is widely expresssed in hematologic malignancies. Haematologica. 2001;86(12)."},{"issue":"17","key":"1849_CR185","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/nejmoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. NEJM Evid. 2019;380(17):1628\u201337. https:\/\/doi.org\/10.1056\/nejmoa1815105.","journal-title":"NEJM Evid"},{"key":"1849_CR186","unstructured":"Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002;62(6)."},{"issue":"11","key":"1849_CR187","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1172\/JCI128571","volume":"129","author":"K Togami","year":"2019","unstructured":"Togami K, Pastika T, Stephansky J, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin InvestJournal Clin Investigation. 2019;129(11):5005\u201319. https:\/\/doi.org\/10.1172\/JCI128571.","journal-title":"J Clin InvestJournal Clin Investigation"},{"issue":"10","key":"1849_CR188","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1200\/JCO-25-02083","volume":"44","author":"N Pemmaraju","year":"2026","unstructured":"Pemmaraju N, Marconi G, Montesinos P, et al. Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2026;44(10):861\u201373. https:\/\/doi.org\/10.1200\/JCO-25-02083.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1849_CR189","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. The Lancet Oncol. 2024;25(3):388\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(23)00674-5.","journal-title":"The Lancet Oncol"},{"key":"1849_CR190","doi-asserted-by":"publisher","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1). https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","DOI":"10.1038\/s41392-025-02269-w"},{"issue":"16","key":"1849_CR191","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.3390\/cancers13164113","volume":"13","author":"FM Uckun","year":"2021","unstructured":"Uckun FM, Lin TL, Mims AS, et al. A clinical phase 1b study of the cd3xcd123 bispecific antibody apvo436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancers (Basel). 2021;13(16):4113. https:\/\/doi.org\/10.3390\/cancers13164113.","journal-title":"Cancers (Basel)"},{"key":"1849_CR192","doi-asserted-by":"publisher","unstructured":"De Gassart A, Le KS, Brune P, et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response. Sci Transl Med. 2021;13(616). https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABJ0835.","DOI":"10.1126\/SCITRANSLMED.ABJ0835"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01849-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01849-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01849-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:43:33Z","timestamp":1791362613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01849-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":192,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1849"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01849-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"17 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a literature review and does not contain any new studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"81"}}